Study Boosts Brain Mitochondria, Rescues Memory in Mice

On September 8, 2025, a pivotal study was published revealing promising advancements in our understanding of mitochondrial function in relation to neurodegenerative diseases. The research indicates that mitochondrial dysfunction is not just a consequence but a potential root cause of conditions like Alzheimer's disease. This discovery opens avenues for innovative treatment approaches aimed at mitigating cognitive decline and enhancing memory functions.

Key Findings

  • Mitochondrial Dysfunction as a Cause: Researchers have established that problems with mitochondria may initiate brain cell degeneration, potentially accelerating neurodegenerative diseases.
  • Activation of G Proteins: Activating G proteins within mitochondria appears to improve cognitive functions in mouse models affected by mitochondrial disorders.
  • Mechanism of Action: The study identified that stimulating mitochondrial G proteins can enhance the assembly of Complex I, a crucial component of the mitochondria linked to energy production.

Mitochondrial Signal Transducers

Many neurodegenerative diseases, including Alzheimer's, have been linked with mitochondrial dysfunction. This connection raises the important question of whether mitochondrial issues directly contribute to the onset of these diseases or merely reflect their progression. The study published in Nature Neuroscience by researchers from Inserm, the Université de Bordeaux, and the Université de Moncton aims to clarify this relationship.

The research team's previous work on guanine nucleotide-binding proteins (G proteins) revealed that these proteins reside not only on the cell's outer membrane but also within mitochondrial membranes, exerting a regulatory influence on energy production. This insight prompted the exploration of whether activating G proteins inside mitochondria could enhance their function and, by extension, cognitive abilities.

Technological Innovations

The researchers developed a tool leveraging the Designer Receptor Exclusively Activated by Designer Drugs (DREADD) framework. This receptor, having been specifically modified, can be activated by an inert "designer drug" such as clozapine-N-oxide (CNO), allowing precise control over G protein activation within mitochondria.

Technology Description Impact
DREADD A receptor altered to inhibit natural activators but activated by a specific designer drug. Enhances control over mitochondrial functions.
High-Resolution Microscopy Method used to verify the receptor's delivery to target mitochondria. Confirms precise localization and functionality of mitoDREADD-Gs.

A Phosphorylation Cascade Triggers Energy Production

The research indicates that the activation of mitoDREADD-Gs using CNO had immediate positive effects on mitochondrial performance, enhancing membrane potential and oxygen consumption rates (OCR) within cells and in hippocampal tissues. The control variant of DREADD, which was not aimed at mitochondria, showed no similar effects.

Giovanni Marsicano, Inserm research director, emphasized, “This work establishes a cause-and-effect link between mitochondrial dysfunction and neurodegenerative symptoms, suggesting impaired mitochondrial activity could trigger neuronal degeneration.”

Memory Rescue in Mouse Models

The researchers proceeded with experiments involving two distinct mouse models of neurodegenerative diseases: one illustrating frontotemporal dementia (FTD) and another resembling Alzheimer's disease. They confirmed these models exhibited diminished mitochondrial respiration and reduced activity of PKA in the hippocampus, the brain region pivotal for memory processes.

Upon expressing mitoDREADD-Gs in these mice and activating it with CNO, their performance in the novel object recognition (NOR) memory test restored to levels comparable with healthy mice. The control DREADD had no impact, reinforcing the specificity of the approach.

Future Directions

Looking ahead, the research team's primary goal is to determine the long-term effects of continuously stimulating mitochondrial activity. They aim to assess whether such stimulation could mitigate symptoms of neurodegenerative diseases, potentially delaying or preventing neuronal loss.

Literature

  1. Pagano Zottola, A. C., et al. (2025). Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice. Nature Neuroscience, 1-14.
  2. Wang, W., et al. (2020). Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Molecular Neurodegeneration, 15(1), 30.
  3. Suofu, Y., et al. (2017). Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proceedings of the National Academy of Sciences, 114(38), E7997-E8006.

The findings in this study not only advance our understanding of mitochondrial involvement in cognitive impairment but may also lead to promising therapeutic strategies for treating neurodegenerative diseases in humans.

For further information, please visit the original article in Nature Neuroscience.